• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

中国东部地区既往治疗肺结核患者中耐多药的危险因素:一项病例对照研究。

Risk factors for multidrug resistance among previously treated patients with tuberculosis in eastern China: a case-control study.

机构信息

Zhejiang Provincial Center for Disease Control and Prevention, Hangzhou, China.

出版信息

Int J Infect Dis. 2013 Dec;17(12):e1116-20. doi: 10.1016/j.ijid.2013.06.006. Epub 2013 Aug 2.

DOI:10.1016/j.ijid.2013.06.006
PMID:23916547
Abstract

BACKGROUND

Previous treatment has been documented as a major risk factor for multidrug-resistant tuberculosis (MDR-TB). However, risk factors for MDR-TB among previously treated patients in China are unclear. This study aimed to ascertain the risk factors for MDR-TB in this particular population in China.

METHODS

A case-control study was conducted from July through August 2011 in five cities of Zhejiang Province. Cases were previously treated TB patients who had disease resistant to at least isoniazid and rifampin, whereas controls were previously treated TB patients who had disease sensitive to isoniazid and rifampin.

RESULTS

Ninety-eight cases and 83 controls were identified. Multivariate analysis showed that a duration of first treatment of more than 8 months (odds ratio (OR) 2.18, 95% confidence interval (CI) 1.05-4.52), more than three prior episodes of anti-TB treatment (more than 2 months of continuous treatment as one episode) (OR 5.57, 95% CI 2.38-13.00), adverse effects of anti-TB medication (OR 3.63, 95% CI 1.79-7.36), and more than three TB foci in the lung (OR 2.17, 95% CI 1.08-4.37) were associated with MDR-TB in previously treated TB patients. Low family income (p=0.056) was marginally significant in the univariate analysis.

CONCLUSIONS

Particular clinical diagnostic results, such as more than three TB foci in the lung, non-standard or irregular therapy, and adverse effects of anti-TB medication, were found to be associated with MDR-TB in previously treated TB patients. High quality directly observed treatment should be strengthened to ensure that the previously treated patients can receive standard and regular regimens.

摘要

背景

既往治疗史是耐多药结核病(MDR-TB)的一个主要危险因素。然而,中国既往治疗患者发生 MDR-TB 的危险因素尚不清楚。本研究旨在确定中国这一特定人群中 MDR-TB 的危险因素。

方法

2011 年 7 月至 8 月在浙江省 5 个城市进行了一项病例对照研究。病例为至少对异烟肼和利福平耐药的既往治疗结核病患者,而对照为对异烟肼和利福平敏感的既往治疗结核病患者。

结果

共确定了 98 例病例和 83 例对照。多因素分析显示,首次治疗持续时间超过 8 个月(比值比(OR)2.18,95%置信区间(CI)1.05-4.52)、既往抗结核治疗次数超过 3 次(超过 2 个月的连续治疗作为一次)(OR 5.57,95% CI 2.38-13.00)、抗结核药物不良反应(OR 3.63,95% CI 1.79-7.36)和肺部结核病灶超过 3 个(OR 2.17,95% CI 1.08-4.37)与既往治疗结核病患者发生 MDR-TB 相关。家庭收入低(p=0.056)在单因素分析中具有显著意义。

结论

肺部结核病灶超过 3 个、非标准或不规则治疗以及抗结核药物不良反应等特定临床诊断结果与既往治疗结核病患者的 MDR-TB 相关。应加强高质量的直接观察治疗,确保既往治疗患者接受标准和规范的治疗方案。

相似文献

1
Risk factors for multidrug resistance among previously treated patients with tuberculosis in eastern China: a case-control study.中国东部地区既往治疗肺结核患者中耐多药的危险因素:一项病例对照研究。
Int J Infect Dis. 2013 Dec;17(12):e1116-20. doi: 10.1016/j.ijid.2013.06.006. Epub 2013 Aug 2.
2
Factors contributing to the high prevalence of multidrug-resistant tuberculosis among previously treated patients: a case-control study from China.既往治疗患者中耐多药结核病高流行率的相关因素:一项来自中国的病例对照研究
Microb Drug Resist. 2014 Aug;20(4):294-300. doi: 10.1089/mdr.2013.0145. Epub 2013 Dec 13.
3
Factors contributing to the high prevalence of multidrug-resistant tuberculosis: a study from China.导致耐多药结核病高发的因素:来自中国的一项研究。
Thorax. 2012 Jul;67(7):632-8. doi: 10.1136/thoraxjnl-2011-200018. Epub 2012 Mar 8.
4
Proportions and Risk Factors of Developing Multidrug Resistance Among Patients with Tuberculosis in China: A Population-Based Case-Control Study.中国结核病患者中发生耐多药的比例及危险因素:一项基于人群的病例对照研究
Microb Drug Resist. 2016 Dec;22(8):717-726. doi: 10.1089/mdr.2015.0186. Epub 2016 Apr 8.
5
Risk factors for multidrug-resistant tuberculosis in Hong Kong.香港耐多药结核病的危险因素。
Int J Tuberc Lung Dis. 2008 Sep;12(9):1065-70.
6
National survey of drug-resistant tuberculosis in China.中国耐药结核病国家调查。
N Engl J Med. 2012 Jun 7;366(23):2161-70. doi: 10.1056/NEJMoa1108789.
7
[Characteristics and treatment outcomes of INH-resistant or RFP-resistant tuberculosis].[耐异烟肼或耐利福平结核病的特征及治疗结果]
Kekkaku. 2003 Oct;78(10):611-7.
8
Risk factors for multidrug resistant tuberculosis patients in Amhara National Regional State.阿姆哈拉民族州耐多药结核病患者的风险因素。
Afr Health Sci. 2015 Jun;15(2):368-77. doi: 10.4314/ahs.v15i2.9.
9
[Prevalence and risk factors on the resistance related to second-line drugs among multi-drug resistant tuberculosis cases in Shanghai, China].[中国上海耐多药结核病患者中二线药物相关耐药情况及危险因素分析]
Zhonghua Liu Xing Bing Xue Za Zhi. 2012 Aug;33(8):796-8.
10
Risk factors associated with fluoroquinolone-resistant tuberculosis in a Beijing tuberculosis referral hospital.与北京结核病转诊医院氟喹诺酮类耐药结核病相关的危险因素。
Respirology. 2011 Aug;16(6):918-25. doi: 10.1111/j.1440-1843.2011.01990.x.

引用本文的文献

1
Determinants of multidrug-resistant tuberculosis among adults undergoing treatment for tuberculosis in Tigray Region, Ethiopia: a case-control study.影响成年人结核病治疗中出现耐多药结核的因素:一项在埃塞俄比亚提格雷地区进行的病例对照研究。
BMJ Open Respir Res. 2024 May 2;11(1):e001999. doi: 10.1136/bmjresp-2023-001999.
2
Drug-resistant tuberculosis: a persistent global health concern.耐药性结核病:一个持续存在的全球健康问题。
Nat Rev Microbiol. 2024 Oct;22(10):617-635. doi: 10.1038/s41579-024-01025-1. Epub 2024 Mar 22.
3
Global prevalence of drug-resistant tuberculosis: a systematic review and meta-analysis.
全球耐药结核病患病率:系统评价和荟萃分析。
Infect Dis Poverty. 2023 May 25;12(1):57. doi: 10.1186/s40249-023-01107-x.
4
Prevalence of multidrug-resistant tuberculosis in East Africa: A systematic review and meta-analysis.东非地区耐多药结核病的流行情况:系统评价和荟萃分析。
PLoS One. 2022 Jun 30;17(6):e0270272. doi: 10.1371/journal.pone.0270272. eCollection 2022.
5
Treatment outcomes of patients with multidrug and extensively drug-resistant tuberculosis in Zhejiang, China.中国浙江耐多药和广泛耐药结核病患者的治疗结果。
Eur J Med Res. 2021 Apr 3;26(1):31. doi: 10.1186/s40001-021-00502-0.
6
Epidemiology of drug-resistant tuberculosis in Chongqing, China: A retrospective observational study from 2010 to 2017.中国重庆耐药结核病的流行病学:2010 年至 2017 年的回顾性观察研究。
PLoS One. 2019 Dec 10;14(12):e0216018. doi: 10.1371/journal.pone.0216018. eCollection 2019.
7
Seroprevalence and associated factors of HSV-2 infection among general population in Shandong Province, China.中国山东省一般人群中单纯疱疹病毒 2 型感染的血清流行率及相关因素。
BMC Infect Dis. 2019 May 6;19(1):382. doi: 10.1186/s12879-019-3995-2.
8
Assessment of the risk factors associated with multidrug-resistant tuberculosis in Sudan: a case-control study.评估苏丹耐多药结核病相关危险因素:病例对照研究。
Epidemiol Health. 2019;41:e2019014. doi: 10.4178/epih.e2019014. Epub 2019 Apr 20.
9
Surveillance of Rifampicin Resistance With GeneXpert MTB/RIF in the National Reference Laboratory for Tuberculosis at the Institut Pasteur in Bangui, 2015-2017.2015 - 2017年在班吉巴斯德研究所国家结核病参考实验室使用GeneXpert MTB/RIF进行利福平耐药监测。
Open Forum Infect Dis. 2019 Feb 22;6(3):ofz075. doi: 10.1093/ofid/ofz075. eCollection 2019 Mar.
10
Evaluation of Xpert MTB-RIF guided diagnosis and treatment of rifampicin-resistant tuberculosis in Indonesia: A retrospective cohort study.评估 Xpert MTB-RIF 指导下的耐利福平结核病的诊断和治疗:一项回顾性队列研究。
PLoS One. 2019 Feb 28;14(2):e0213017. doi: 10.1371/journal.pone.0213017. eCollection 2019.